Dupont Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Dupont Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-33,857	Closed	-$484K	–	1037
2022 Q4	$484K	Buy	33,857 +3,988	+13%	+$62.8K	0.02%	574
2022 Q3	$763K	Buy	29,869 +2,052	+7%	+$51.5K	0.05%	492
2022 Q2	$790K	Buy	27,817 +2,354	+9%	+$74.6K	0.04%	554
2022 Q1	$898K	Sell	25,463 -16,506	-39%	-$553K	0.04%	565
2021 Q4	$1.76M	Buy	41,969 +40,113	+2,161%	+$1.62M	0.06%	314
2021 Q3	$91K	Sell	1,856 -9,518	-84%	-$464K	﹤0.01%	1354
2021 Q2	$475K	Buy	+11,374	New	+$441K	0.01%	1029

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Dupont Capital Management's MRVI Position: Q1 2023 in Review

Dupont Capital Management sold out of Maravai LifeSciences (MRVI) in Q1 2023, closing a stake of 33,857 shares — an estimated $484K sold.

Dupont Capital Management first reported a position in MRVI in Q2 2021 and held it in 7 quarters. The position peaked at $1.76M in Q4 2021. 219 funds tracked by Wall St. Rank hold MRVI as of Q1 2023.

Dupont Capital Management reported no remaining Maravai LifeSciences position as of Q1 2023 after selling out during the quarter.
Dupont Capital Management sold 33,857 Maravai LifeSciences shares in Q1 2023, an estimated $484K.
Dupont Capital Management first reported a position in Maravai LifeSciences in Q2 2021 and held it in 7 quarters.
Dupont Capital Management's Maravai LifeSciences position peaked at $1.76M in Q4 2021.
219 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2023.

Based on Dupont Capital Management's 13F filing for Q1 2023, filed 28 Apr 2023.